EVOLUS BROADENS ITS U.S. PRODUCT PORTFOLIO WITH THE ADDITION OF EVOLYSSE™
DISCLOSURES

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; timing and success of clinical development and regulatory approval of Evolysse™; the expected product profile of Evolysse™; the market growth for our products; our ability to meet our goals related to the market position of our products; the potential market acceptance; demand market size, adoption rate, revenue expectations, future results of our product and related loyalty programs, and timing and results of the company’s proposed Phase II clinical trial, the potential performance profile of an extra-strength dose, are forward-looking statements. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the success of the launch of Jeuveau®, the regulatory approval and success of the launch of Evolysse™, customer and consumer adoption of the products, competition and market dynamics, the efficiency and operability of our digital platform, the ability to successfully complete the Phase II clinical trial, ability to achieve FDA approval and ultimate commercial acceptability and pricing for an “extra-strength” Jeuveau® dose, our ability to comply with our settlement agreement with Medytox, and our ability to maintain regulatory approval of Jeuveau® and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled “Risk Factors” in our Quarterly Report on Form 10-Q for the year ended March 31, 2023 that was filed with the Securities and Exchange Commission on May 9, 2023 and any subsequent filings, each of which is available online at www.sec.gov.

All written and verbal forward-looking statements attributable to our Company or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. We may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

This presentation contains information regarding the Evolysse™ line of dermal fillers which are medical devices that have not yet been approved by the U.S. Food and Drug Administration. The devices are currently in various stages of the regulatory approval process. Any statements made regarding any device’s potential benefits or market potential are based on current expectations and are subject to change.

Certain of the industry, statistical and market data in this presentation was obtained from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, which could cause results to differ materially from those expressed in the estimates made by third parties and by us. Evolus”, ”Jeuveau”, and Evolysse ™ are three of our trademarks that are used in this presentation. Restalyne®, OBT® and XpresHAn™ are trademarks of Galderma Holdings SA. All other marks are the property of their respective owners.
OVERVIEW

HIGHLY COMPETITIVE FILLER LINE

• Evolysse™ is the first-generation cold technology HA line by Symatese with 5 fillers in late-stage clinical development with indications including mid face, nasolabial folds, lips and eyes
• In partnership with Symatese who developed the latest generation of Restylane® products in the United States based on XpresHAn Technology™/OBT®

RAISING 2028 REVENUE OUTLOOK FROM $500M TO $700M

• Increasing guidance by $200M in 2028 based on 2 product launches in 2025, 1 product launch in 2026 and 2 product launches in 2027

HIGHLY CAPITAL EFFICIENT AGREEMENT

• Minimal short-term dilution delivering material long-term value accretion
• Funded to profitability with $50M Pharmakon tranche
• Leverage existing sales force, digital infrastructure, Evolus Rewards and co-branded media
A PERFECT PARTNERSHIP
PERFORMANCE BEAUTY
SCALABLE COMMERCIAL PLATFORM

- Leadership with deep experience in clinical development and commercial launch of injectables
- Established and growing customer base and consumer loyalty program
- Market differentiated co-branded media partnership with aesthetic practices
- Scalable digital infrastructure designed to seamlessly integrate additional products
THE SCIENCE OF TISSUE REGENERATION & RECONSTRUCTION
UNIQUE AND COMBINED EXPERTISE IN THE FIELD OF HYALURONIC ACID AND INJECTION SYSTEMS, COLLAGENS AND SILICONES

SINCE 1997

EXPERIENCED LEADERSHIP TEAM

25+ MILLION PATIENTS TREATED PER YEAR

15+ MEDICAL SPECIALITIES: AESTHETIC MEDICINE, PLASTIC SURGERY, ORTHOPEDICS, RHEUMATOLOGY, WOUND CARE

PRIVATELY-HELD FRENCH COMPANY WITH INTERNATIONAL PRESENCE & 4 PLANTS

EMPLOYEES 380+ RESEARCHERS 40+
**SYMATESE SCIENCE GENESIS**

25+ YEARS IN R&D AND MANUFACTURING OF AESTHETICS & MEDICAL BIOMATERIALS

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1997</td>
<td>SYMATESE FOUNDED BY INDUSTRY EXPERTS</td>
</tr>
<tr>
<td>2003</td>
<td>LAUNCHED FIRST 2 PRODUCTS: HEMOTÈSE® &amp; COLLAPAT®II</td>
</tr>
<tr>
<td>2004</td>
<td>ENTERED PARTNERSHIP WITH L’ORÉAL</td>
</tr>
<tr>
<td>2007</td>
<td>PEROUSE PLASTIE BREAST IMPLANTS SOLD TO MENTOR</td>
</tr>
<tr>
<td>2011</td>
<td>SOLD RIGHTS OF XpresHAntotechnology™/OBT® AND RELATED DERMAL FILLERS TO GALDERMA</td>
</tr>
<tr>
<td>2013</td>
<td>LAUNCH OF NEVELIA®, DERMAL REGENERATION MATRIX</td>
</tr>
<tr>
<td>2021</td>
<td>R&amp;D PARTNERSHIP STRENGTHENED WITH L’ORÉAL ON BIOMATERIALS</td>
</tr>
</tbody>
</table>

**ouserful**
EVOLYSSE™, AN INNOVATIVE TECHNOLOGY THAT COMPLEMENTS THE JEUVEAU® BRAND
**EVOLYSSE™ MANUFACTURING**  
FIRST-GENERATION COLD TECHNOLOGY HA BY SYMATESE

**CROSS-LINKING HA**  
Typical cross-linking: At **high temperature**  
Symatese cross-linking: At **low temperature**

**BENEFIT**  
- Cross-linking technology that better preserves the hyaluronic acid chain designed for dynamic performance and efficacy  
- Less fragmentation aims to improve safety for the benefit of practitioners and their patients

---

HOT

COLD
EVOLYSSE™ PRODUCT LINE

**2025 | LAUNCH**

**EVOLYSSE™ LIFT**
NASOLABIAL FOLDS

**EVOLYSSE™ SMOOTH**
NASOLABIAL FOLDS

**2026 | LAUNCH**

**EVOLYSSE™ SCULPT**
MID-FACE VOLUME

**2027 | LAUNCH**

**EVOLYSSE™ EYE**
INFRAORBITAL HOLLWOS

**EVOLYSSE™ LIPS**
VOLUMIZING AND CONTOURING

MAY 2023
PORTFOLIO OF BRANDS

JEUVEAU®
- PrabotulinumtoxinA-xvfs injection

EVOLYSSE™
5 Indications
- 2 in 2025 (Smooth, Lift)¹
- 1 in 2026 (Sculpt)¹
- 2 in 2027 (Eyes, Lips)¹

¹. Expected launches subject to prior FDA approval
FACIAL FILLERS:
A LARGE AND GROWING MARKET OPPORTUNITY
U.S. FILLER MARKET
MARKET NEARLY DOUBLES TO $3 BN¹ BY 2028

TOTAL U.S. FILLER MARKET ($BN)¹

2022 2023 2024 2025 2026 2027 2028
1.6 1.8 2.0 2.2 2.4 2.7 3.0

10% CAGR¹

2028: TAM² EXPANDS BY 70%
$14 BN¹ U.S. AESTHETIC MARKET

ALL OTHER FILLER TOXIN

28%
21%

2. Total Addressable Market
TOXINS AND FILLERS ARE THE TOP 2 MEDICAL AESTHETIC PROCEDURES¹

FILLERS ARE THE #2 SERVICE PROVIDED ACROSS ALL CHANNELS¹

<table>
<thead>
<tr>
<th>Category</th>
<th>Toxins</th>
<th>Filler</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plastic Surgeons</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatologists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med Spas</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FILLERS ARE THE #1 ADD-ON PROCEDURE FOR TOXIN USERS¹

- Filler: 34%
- Skincare: 21%
- Laser Hair Removal: 21%
- Energy-Based Devices: 15%
- Body Contouring: 10%

¹. Source: BCG Aesthetic Research Presented at IMCAS 2023
TRANSACTION TERMS AND FINANCIAL IMPACT
KEY BUSINESS TERMS AND FINANCIALS

- Consideration for exclusive U.S. rights
  - Milestone payments of €16.2M, with €4.1M upon signing and 4 additional annual payments starting June of 2025
  - Shared cost for U.S. registration for 2 indications that will launch in 2027
- Transfer price and mid-single digit royalty on net sales
- Minimum commitment on purchase volumes
- Term of 15 years with automatic 5-year extension terms
- Fully funded to profitability with $50M Pharmakon debt
THANK YOU

www.evolus.com